PRIMARY STUDY
Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
Key Findings: This review covers the existing knowledge base on the endocannabinoid system (ECS) and CB1 and CB2 receptors and their involvement in the development and progression of non-alcoholic fatty-liver disorder (NAFLD). A better understanding of this interaction could lead to potential therapeutic uses for cannabinoids in the treatment of NAFLD.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Poland
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Tetrahydrocannabinolic Acid (THC-a), Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Endocannabinoid (unspecified), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1, CB2, PPAR - Alpha, PPAR - Beta Delta, PPAR - Gamma, PPARs
